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Abstract
The Wnt/b-catenin signal transduction pathway regulates a broad range of developmental processes. Aberrant activation of
the Wnt pathway leads to cancer and degenerative diseases. b-catenin is a key signaling molecule that is frequently used as
a direct monitor of Wnt pathway activation. This paper describes a multi-parametric method for quantitative analysis of
cellular b-catenin protein levels in a rapid and high-throughput manner. The assay offers temporally resolved detection of
Wnt-stimulated accumulation of b-catenin, simultaneously detecting cell number, and it sheds light onto the kinetics of
posttranslational stabilization of b-catenin.
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Introduction
The Wnt/b-catenin canonical pathway plays key roles in
development and in the progression of several types of human
cancer [1,2,3]. b-catenin is an important positive regulator of this
signaling pathway, and is dephosphorylated and subsequently
stabilized upon binding of Wnt ligands to the cell surface. A
consequence of this increase in cytoplasmic b-catenin levels is the
concomitant translocation of b-catenin to the nucleus where it
interacts with transcriptional coactivators to initiate transcription
of Wnt target genes. Since b-catenin is critical for relaying the Wnt
signal, researchers frequently quantify total cellular levels of b-
catenin to measure Wnt response or to detect perturbations of the
pathway. The standard detection method relies on gel electro-
phoresis coupled with western blotting to quantify total endoge-
nous protein. The limitations of this method are that it is low-
throughput, requires large number of cells and contains inherent
variability due to gel lane loading, thus hindering the rapid parallel
analysis of multiple samples. Other methods for detecting b-
catenin stabilization rely on the expression of b-catenin fused to
genetically-encoded reporters such as green fluorescent protein
(GFP) or luciferase [4,5], but these may result in artifacts due to b-
catenin over expression. Cellular toxicity due to transfection is
another frequently encountered problem.
Results and Discussion
I developed a rapid, quantitative and high-throughput method
for measuring Wnt-induced changes in endogenous b-catenin
levels. The assay employs mouse L-cells because they are an
established model system for studying Wnt signaling [6]. b-catenin
in L-cells is predominantly distributed in the cytoplasm and is not
present at cell junctions, allowing direct measurement of changes
in Wnt-responsive cytoplasmic b-catenin pools. After seeding in a
384-well plate at a density of 5000 cells/well for 24 h, cells were
stimulated with purified Wnt3a ligand for 10 h at 37uC. The cells
were then fixed and processed for staining with fluorophores in the
infrared range to simultaneously detect b-catenin and nuclei
(Figure 1A). Anti-b-catenin antibody concentration was opti-
mized for best signal to background ratio (see methods), detected
by secondary IR800 antibody (800 nm). DNA staining with
DRAQ5 dye [7] (700 nm) was used as a marker to normalize b-
catenin signal for cell number, particularly important for
monitoring a pathway known to affect proliferation [8]. Whole-
cell fluorescent images of entire wells were acquired at low
resolution at 700 nm (red) and 800 nm (green) (Figure 1B). L-
cells stimulated with Wnt3a ligand exhibit 11-fold elevated levels
of total b-catenin compared to non-stimulated cells without
changes in the total DNA content as shown by an increase in
the green signal, making the merged signal more yellow than red
(Figure 1B, C). The assay is highly reproducible with a standard
deviation within 10% of the mean of replicates (n=4). Moreover,
there is an excellent linear correlation (R
2=0.997) between the
measured DNA fluorescence and the actual number of cells plated
in each well (Figure 1D), thus allowing for sensitive monitoring of
fluctuations in cell number under various treatment conditions.
Because the assay is conducted in a 384-well plate format, it
minimizes reagent usage and is readily scalable. For example, an
entire dose response curve of Wnt3a in quadruplicate can be
obtained in 6 h using one 384-well plate (Figure 1E). All of this is
in sharp contrast to the standard method of preparing individual
lysates for analyzing b-catenin by western blotting.
To validate the sensitivity of the assay, intracellular b-catenin
levels were measured in response to various treatments known to
modulate the Wnt/b-catenin pathway. GSK3b is a serine-threonine
kinase involved in b–catenin phosphorylation, leading to its
degradation [9,10]. L-cells treated with the GSK3b inhibitor LiCl
(50 mM) [11] or the proteasome/calpain inhibitor MG132 (25 mM)
[12] showed a marked increase in b-catenin fluorescence within 30–
60 min (Figure 2A). L-cells treated with Wnt3a (100 ng/ml)
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(Figure 2A). As expected, treatment with Wnt3a in the presence of
quercetin (100 mM), a natural product that inhibits Wnt/b-catenin
signaling without altering cytosolic b-catenin levels [13], had no
effect on time-dependent b-catenin response (Figure 2B). Similarly,
treatment with Wnt3a in the presence of the Wnt inhibitor ICG-001
(10 mM) [14] that acts downstream of b-catenin had no significant
effects on b-catenin stabilization as expected (Figure S1). These
examples illustrate the power of our assay to temporally resolve
intracellular levels of b-catenin under various conditions, and to
readily detect the fast response of b-catenin to GSK3b or
proteasome inhibitors at relatively short treatment times. In
summary, this new method is versatile and can be readily adapted
to a high-throughput format. It can also be utilized for assessing the
cellulareffects of inhibitors of GSK3b on b-cateninaccumulation, or
for screening compounds for Wnt pathway inhibition.
To determine if the increase in b-catenin fluorescence upon
Wnt3a addition reflects posttranslational stabilization of b-catenin
or new protein synthesis, L-cells were treated with either
cycloheximide, a protein synthesis inhibitor, or actinomycin D, a
DNA transcription inhibitor. Over 6 h, Wnt3a-dependent accu-
mulation of b-catenin shows an almost indistinguishable profile in
the absence or presence of actinomycin D, but is severely impacted
upon treatment with cycloheximide (Figure 3). This shows that
protein translation is absolutely required for Wnt-mediated
accumulation of b-catenin; it also suggests that in the early phase
Figure 1. Description and validation of a quantitative method for temporal detection of cellular b-catenin. (A) Schematic of the assay.
m denotes mouse species. (B) A representative output infrared image of L-cells treated with or without Wnt3a (100 ng/ml) for 10 h. The image shows
whole-cell fluorescence from actual wells of a 384-well plate, highlighting increase in b-catenin signal (green, 700 nm) without change in cellular DNA
content (red, 800 nm, detected by DRAQ5). (C) Quantification of the b-catenin signal from (B). The signal is background subtracted and normalized to
DNA fluorescence. Values represent the mean6SEM from quadruplicate experiments. (D) Linearity of measured DNA fluorescence (DRAQ5 signal)
versus actual number of L-cells plated per well. (E) Dose titration of Wnt3a at 24 h illustrating half-maximal activation of cellular b-catenin in L-cells
occurs at 33 ng/ml ligand.
doi:10.1371/journal.pone.0003498.g001
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mRNA pools and is not translationally derived from newly
transcribed mRNA.
Little is known about the experimental rate of accumulation of
endogenous b-catenin upon Wnt activation in mammalian cells.
To develop a better quantitative understanding of the Wnt/b-
catenin pathway, I determined the initial rate of accumulation of
cellular b–catenin upon Wnt pathway activation and studied in
detail its dependence on Wnt3a concentration in L-cells. A
simplified kinetic model [15] of the Wnt/b-catenin pathway
depicts that under basal conditions b-catenin is degraded due to a
predominantly high rate of phosphorylation (Figure 4A). The
presence of Wnt3a inhibits phosphorylation of b-catenin, thus
stabilizing b-catenin and preventing its proteasomal degradation
(Figure 4A). The model assumes that the intrinsic turnover rate of
b-catenin through mechanisms other than phosphorylation and
that are independent of Wnt is minimal. First, the effective Wnt3a
concentration (EC50) for half-maximal accumulation of intracel-
lular b-catenin was calculated and shown to depend on the period
of stimulation (Figure 4B, C). For example, the EC50 is ,30 ng/
ml for 4 h–35 h and ,50–70 ng/ml for only 1 h–2 h stimulation
with Wnt3a (Figure 4C). These measurements define the
sensitivity of the assay and establish optimal conditions for usage.
Furthermore, b-catenin levels are upregulated within 30 mins
after Wnt3a stimulation, exhibit a noticeable increase in intensity
between 6–8 h, and start to plateau after 10 h (Figure 4D). The
rate of b–catenin accumulation reflects its rate of cellular
translation, which varies according to the concentration of Wnt3a
presented to cells. At Wnt3a concentrations lower than ,50 ng/
ml, there is a linear correlation between initial rate and Wnt3a
Figure 2. Monitoring cellular b-catenin accumulation in re-
sponse to various stimuli. (A) L-cells were treated with either Wnt3a
(50 ng/ml), LiCl (50 mM) or MG132 (25 mM) for the indicated periods of
time and processed for imaging as described in methods. (B)
Monitoring the effects of a pharmacologic inhibitor of Wnt signaling
on b-catenin accumulation. L-cells were treated with Wnt3a (50 ng/ml)
in the absence or presence of 100 mM quercetin for the indicated times.
Each point represents mean6SEM (n=3–4).
doi:10.1371/journal.pone.0003498.g002
Figure 3. Dependence of Wnt3a-driven accumulation of
cellular b-catenin on new protein but not RNA synthesis. L-
cells were treated with Wnt3a (50 ng/ml) in the absence or presence of
either cycloheximide (CHX, 100 mg/ml) or actinomycin D (ActD, 1 mM)
and incubated for the indicated times (n=4).
doi:10.1371/journal.pone.0003498.g003
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The model assumes negligible b-catenin turnover in the presence of Wnt3a activation. K1 and K2 denote the rate constants of b-catenin translation
and phosphorylation, respectively. (B) Time- and dose-dependent accumulation of cellular b-catenin. L-cells were incubated with varying
concentrations of Wnt3a for the indicated times. (C) Dose titration of Wnt3a at various time points. The curves are fitted to a non-linear variable slope
sigmoidal equation (R
2 values 0.990–0.999). (D) Kinetics of b-catenin accumulation at different Wnt3a concentrations. The curves are fitted to a non-
linear polynomial equation (R
2 values 0.970–0.999). (E, F) Initial rates of cellular b-catenin accumulation as a function of Wnt3a concentration. Rates
were calculated from slopes of the fitted lines during the initial 2 h of treatment. FI. h
21 denotes fluorescence intensity per hour. All plots are
representative of two independent experiments, each carried out in quadruplicate.
doi:10.1371/journal.pone.0003498.g004
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21
at 1.6 ng/ml Wnt3a and increases by 4-fold upon quadrupling the
concentration of Wnt3a (Figure 4F). However, at Wnt3a
concentrations higher than ,50 ng/ml, this linear relationship is
lost as intracellular b-catenin starts to reach steady-state pools (see
inflection and plateau in Figure 4E, F). In summary, the method
reveals an unprecedented level of detail about the rate of
accumulation of intracellular b-catenin, and is useful for deriving
quantitative kinetic parameters about the Wnt/b-catenin pathway
that may serve as basis for future kinetic modeling of the pathway
[15]. Further investigation into the kinetic rate of b-catenin
degradation is beyond the scope of this paper.
In conclusion, probing Wnt signaling at the cellular level in a
quantitative manner is essential to understanding the signaling
cascades implicated in this pathway. The described multi-
parametric method is a rapid way to quantify levels of endogenous
b-catenin and identify non-specific cytotoxic conditions that result
in artifactual readouts. The assay is high-throughput and
economical since it is conducted in a 384-well plate format and
hence utilizes very small amounts of the expensive purified Wnt3a
material. It also offers reproducibility and great speed compared to
gel electrophoresis and western blotting. It can easily be used as a
secondary screening assay to quickly assess whether pharmacologic
inhibitors of Wnt/b-catenin signaling act upstream or downstream
of b-catenin. For example, the Wnt inhibitor quercetin has no
effect on Wnt-mediated b-catenin accumulation, indicating that it
acts downstream of b-catenin. The limitation of the current
method, however, is that it lacks spatial resolution and thus does
not provide information on the cytoplasmic or nuclear localization
of b-catenin nor its translocation behavior. Nevertheless, this assay
is a quick diagnostic readout for (1) screening and validating the
mechanism of action of modulators of b-catenin or GSK3b, and
(2) quantifying the basal and Wnt-induced expression levels of b-
catenin across different cell types [16]. In addition, this method
offers temporal dynamic resolution and thus can be used to




Mouse fibroblast L-cells were obtained from ATCC, main-
tained as per the manufacturer’s recommendations in growth
medium (DMEM/10% fetal bovine serum) in an incubator at
37uC and 5% CO2. Cell-Bind
TM 384-well plates and monoclonal
anti-b-catenin antibody [cat # 610154] were purchased from
Becton-Dickinson (San Jose, CA). Anti-mouse IRDye800CW and
DRAQ5 (far-red) were obtained from Rockland (Gilbertsville, PA).
All chemicals were purchased from Sigma (St. Louis, MO). ICG-
001, prepared according to literature precedence [14], was from
Janet Gunzner (Genentech Inc.). Mouse Wnt3a, purified from
mouse L-cells as described earlier [17], was obtained from James
Ernst (Genentech Inc.).
Cellular b-catenin Assay
On Day 1, L-cells (5000 cells/20 ml/well) were seeded in a clear
bottomed, black walled 384-well plate and grown for 24 h at
37uC/5% CO2 (The method quantitatively detects b-catenin
levels in other cell lines such as SW480, HCT15 (colorectal cancer)
and U2OS (osteosarcoma); Figure S2. Cell densities are as
follows: SW480: 6000 cells/well, U2OS: 5000 cells/well, HCT15:
6000 cells/well). On Day 2, the cells were treated with 20 mlo fa
26stock of Wnt3a dissolved in growth medium at the indicated
concentration and then incubated for the desired amount of time
at 37uC/5% CO2. For treatment with various stimuli or inhibitors,
20 mlo f2 6stock of chemicals dissolved in growth medium such
that the DMSO concentration did not exceed 0.5% were added to
the wells and then incubated for the desired amount of time. The
cells were then fixed in 4% PFA by adding 20 ml of 12% PFA
directly to the wells for 1 h at room temperature. The wells were
washed three times with PBS (50 ml/well), permeabilized with
PBS/0.1% Triton X-100 (50 ml/well, three times, 2 mins each),
and blocked in LI-COR buffer (50 ml/well) for 2 hours at room
temperature (or alternatively overnight at 4uC). The wells were
then incubated with mouse anti-b-catenin antibody (1: 200 for
optimal signal-to-noise ratio) in LI-COR blocking buffer for
2 hours at room temperature (20 ml/well) and subsequently
washed with PBS/0.1% Tween-20 (50 ml/well, three times).
Infrared anti-mouse IRDye800CW secondary antibody (1: 200)
and DRAQ5 (1: 10,000) in PBS/0.5% Tween-20 were then added
(20 ml/well). The plates were incubated for 1 hour at room
temperature, and the wells were washed with PBS/0.1% Tween-
20 (three times) and incubated in PBS (50 ml/well). The plates
were covered with black seals and imaged on an Odyssey infrared
scanner using microplate2 settings with sensitivity of 5 in both the
700 and 800 nm wavelength channels. Data were acquired by
using Odyssey software, exported and analyzed in Excel (Micro-
soft, Redmond, WA) or KaleidaGraph (Synergy Software). b-
catenin values were background subtracted from wells treated only
with secondary antibody, and then normalized to cell numbers by
dividing by the total DNA fluorescence signal.
Supporting Information
Figure S1 Monitoring cellular b-catenin accumulation in
response to the Wnt/b-catenin pathway inhibitor ICG-001. L-
cells were treated with Wnt3a (50 ng/ml) in the absence or
presence of 10 mM ICG-001 for the indicated times. Each point
represents mean6SEM (n=4).
Found at: doi:10.1371/journal.pone.0003498.s001 (0.27 MB TIF)
Figure S2 Detection of cellular b-catenin in osteosarcoma
U2OS cells, and SW480 and HCT15 colon cancer cell lines. (A)
Titration of b-catenin mAb. U2OS cells were incubated in the
absence of presence of Wnt3a (50 ng/ml) for 24 h. (B) Detection
of b-catenin in SW480 and HCT15 cell lines. m denotes mouse
species.
Found at: doi:10.1371/journal.pone.0003498.s002 (0.20 MB TIF)
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